Cox proportional hazards analysis of clinical factors associated with survival in VEXAS syndrome
| . | Univariable . | Multivariable* . | ||
|---|---|---|---|---|
| . | Hazard ratio (95% CI) . | P value . | Hazard ratio (95% CI) . | P value . |
| Ear chondritis | 0.24 (0.09-0.61) | <.01 | 0.32 (0.12-0.90) | .03 |
| Val variant | 3.49 (1.47-8.32) | <.01 | 2.56 (1.01-6.47) | .05 |
| Transfusion dependence† | 4.56 (1.87-11.08) | .03 | 4.47 (1.79-11.18) | <.01 |
| Myelodysplastic syndrome† | 2.44 (0.92-6.50) | .07 | ||
| Nose chondritis | 0.44 (0.15-1.13) | .10 | ||
| Age at disease onset | 1.00 (0.98-1.11) | .12 | ||
| Unprovoked DVT | 0.49 (0.17-1.25) | .14 | ||
| Lower extremity edema | 0.55 (0.20-1.38) | .22 | ||
| Use of DMARDs | 0.20 (0.11-1.56) | .23 | ||
| Fever | 3.19 (0.65-1.52) | .25 | ||
| Arthritis | 0.70 (0.28-1.70) | .42 | ||
| Testicular pain/swelling | 0.78 (0.28-1.74) | .42 | ||
| Hearing loss | 1.49 (0.44-4.23) | .45 | ||
| UBA1 VAF | 0.98 (0.94-1.03) | .52 | ||
| Pleural effusion | 1.28 (0.44-3.21) | .63 | ||
| Periorbital edema | 3.61 (0.36-2.92) | .82 | ||
| Eye inflammation | 1.32 (0.36-2.91) | .85 | ||
| Skin involvement | 1.05 (0.38-3.72) | .92 | ||
| Pulmonary infiltrates | 0.96 (0.39-2.48) | .94 | ||
| . | Univariable . | Multivariable* . | ||
|---|---|---|---|---|
| . | Hazard ratio (95% CI) . | P value . | Hazard ratio (95% CI) . | P value . |
| Ear chondritis | 0.24 (0.09-0.61) | <.01 | 0.32 (0.12-0.90) | .03 |
| Val variant | 3.49 (1.47-8.32) | <.01 | 2.56 (1.01-6.47) | .05 |
| Transfusion dependence† | 4.56 (1.87-11.08) | .03 | 4.47 (1.79-11.18) | <.01 |
| Myelodysplastic syndrome† | 2.44 (0.92-6.50) | .07 | ||
| Nose chondritis | 0.44 (0.15-1.13) | .10 | ||
| Age at disease onset | 1.00 (0.98-1.11) | .12 | ||
| Unprovoked DVT | 0.49 (0.17-1.25) | .14 | ||
| Lower extremity edema | 0.55 (0.20-1.38) | .22 | ||
| Use of DMARDs | 0.20 (0.11-1.56) | .23 | ||
| Fever | 3.19 (0.65-1.52) | .25 | ||
| Arthritis | 0.70 (0.28-1.70) | .42 | ||
| Testicular pain/swelling | 0.78 (0.28-1.74) | .42 | ||
| Hearing loss | 1.49 (0.44-4.23) | .45 | ||
| UBA1 VAF | 0.98 (0.94-1.03) | .52 | ||
| Pleural effusion | 1.28 (0.44-3.21) | .63 | ||
| Periorbital edema | 3.61 (0.36-2.92) | .82 | ||
| Eye inflammation | 1.32 (0.36-2.91) | .85 | ||
| Skin involvement | 1.05 (0.38-3.72) | .92 | ||
| Pulmonary infiltrates | 0.96 (0.39-2.48) | .94 | ||